New Research Shows Biopixlars Unique Bioprinting Capacity

In a scientific article published today in Scientific Reports, researchers at Fluicell AB in collaboration with Cellectricon AB and Karolinska Institutet, demonstrate generation of complex 3D biological tissues using the single-cell bioprinting platform Biopixlar.  The paper present new and exciting possibilities for Biopixlar®-printed tissues to be used in drug testing and disease modelling.

Establishing biologically relevant in vitro systems for disease modelling has, for a long time, been a challenge due to the lack of micro-environmental control necessary to replicate human tissue and organ histology. In the new study, the team of scientists show how Biopixlar allows researchers to position individual cells in complex patterns enabling them to create biological tissues with the same high precision as in human tissues. The biological relevance created by Biopixlar’s high-resolution bioprinting technology allow created tissues to be used for drug testing and disease modeling.

Because of its versatility, Biopixlar offers many new opportunities for researchers. With it, we can print everything from tissues such as  tissue types, including skin, liver, and a variety of cancer models using human histology as a template. And importantly, more than 95% of the cells that you print stay alive. Dr. Tatsiana Lobovkina, CSO of Fluicell comments.

The ability to positions cells right where and when you want them, not only allows researchers to create in vitro biological tissues, but also opens up new possibilities for applications within personlized medicine and advanced therapies.

Being able to directly control the local environment around cells is very important for directing stem cell development, a key aspect in tissue generation for regenerative or therapeutic applications. We believe that this will allow Biopixlar to be a very valuable tool, not just for research, but also for development on new therapies, Dr. Gavin Jeffries, CTO of Fluicell, comments.

Biopixlar is a game-changing technology and sets a new standard for facile, true-to-the original, high-resolution bioprinting. It has all the key attributes to become a highly important player in translational drug discovery and therapeutic development, Prof. Owe Orwar, Karolinska Institutet and Fluicell board member comments.

The work presented in the article 3D micro-organisation printing of mammalian cells to generate biological tissues, published today in Scientific Reports, is a collaboration between researchers from Fluicell AB, Cellectricon AB and Karolinska Institutet. Scientific Reports is an online open-access journal published by Nature Research.